21.20 -0.24 (-1.12%)
After hours: 5:55PM EST
|Bid||21.05 x 900|
|Ask||21.30 x 1300|
|Day's Range||19.71 - 21.46|
|52 Week Range||13.03 - 22.75|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||24.69|
Biotechnology company Moderna Inc. was mentioned during Wednesday night's Lightning Round on Jim Cramer's Mad Money program. Cramer said, "This is a speculative one, but these guys are winners.
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on Feb. 12) Abbott Laboratories (NYSE: ABT ) Amphastar Pharmaceuticals ...
In a clinical trial of 124 adult subjects, a single dose of the vaccine was linked to a three- to six-fold increase in virus-fighting antibodies, according to Moderna.
Moderna, Inc., (MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced topline data from the first planned interim analysis of safety and immunogenicity from its Phase 1 study of mRNA-1653 in healthy adults.
BioNTech is speaking with advisers about holding a share sale as early as this year, the people said, asking not to be identified because the deliberations are private. Potential advisers have suggested the firm, which develops personalized cancer vaccines, could be valued at about $5 billion in an IPO, though the planning is at an early stage and the ultimate value will depend on investor demand, they said. No final decisions have been made and BioNTech could remain private for longer or choose to raise financing privately first, the people said.
Moderna, Inc., (MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced the dosing of the first subject in a Phase 1 clinical trial evaluating the safety and tolerability of escalating doses of mRNA-1944 via intravenous infusion in healthy adults. This is the first monoclonal antibody encoded by mRNA to be dosed in a human and the first development candidate from the Company’s systemic therapeutics modalities to start clinical testing.
NEW YORK, NY / ACCESSWIRE / January 31, 2019 / U.S. equities regained footing on Wednesday as investors cheered the latest round of corporate earnings and the Federal Reserve kept the interest rates unchanged ...
Moderna, Inc., (MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced the publication of pre-clinical data that shows the therapeutic potential of mRNA-2752, an investigational mRNA immuno-oncology therapy that encodes a novel combination of three immunomodulators designed to activate the immune system to recognize and eradicate tumors that are resistant to checkpoint inhibitors. The study, published in the scientific journal Science Translational Medicine, found that the local delivery of mRNA encoding the secreted cytokines IL23 and IL36γ and the membrane-bound T-cell co-stimulator OX40L, induced a broad immune response promoting tumor regression in both injected lesions and distant un-injected tumors in mice.
Moderna, Inc. (MRNA), a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that John Mendlein, Ph.D., President of Corporate and Product Strategy, will be leaving the Company effective February 1, 2019 to join Flagship Pioneering as an Executive Partner.
NEW YORK, NY / ACCESSWIRE / January 14, 2019 / U.S. equities posted strong weekly gains, however, stock closed lower for the day on Friday on concerns over an ongoing U.S. government shutdown and worries ...
just went public on Dec 7, to an immediate "Strong Buy" rating from eight market analysts. In an impressive open, and the biotech sector's largest IPO, the company raised over $600 million to reach a total value of about $7.4 billion. The company takes a novel approach to the creation of new drugs, basing its research on mRNA, the genetic material that transfers instructions from DNA into completed proteins.
Moderna Inc. (MRNA) soared 4.2% to $16.95 per share on the New York Stock Exchange on Tuesday after the Cambridge, Massachusetts-headquartered biotechnology company had issued an update on several of its pipeline programs. Warning! GuruFocus has detected 1 Warning Sign with MRNA.
Modern's pipeline of mRNA candidates, which are being developed for several cancer indications and rare diseases, is progressing well.
Moderna stock spiked Tuesday after the newly public biotech company announced a series of updates to its immuno-oncology and rare diseases programs. Moderna is still 29% off its IPO price.
Roughly a month after breaking biotech IPO records to launch as a public company, Cambridge's Moderna Therapeutics Inc. announced plans Tuesday to start several new clinical trials, including a test of its first rare disease treatment.
were rising between 1.5% and 4% in early trading Tuesday after the biotechnology company said it was making positive progress on several of its trial-stage drugs, including treatment for advanced ovarian cancer. Moderna shares were up a little more than 3% at $16.78 on the Nasdaq Stock Exchange after ending the day Monday at $16.27. In a statement Tuesday, Moderna said it has submitted a so-called "investigational new drug," or IND amendment to the Food and Drug Administration to launch a phase 2 study of its treatment for advanced ovarian cancer.
Shares of Moderna Inc. rallied 7.7% in premarket trade Tuesday, after the biotechnology company provided details on recent progress made on its immuno-oncology programs. The company, which became the largest biotech initial public offering when it went public a month ago, said it has submitted a an investigational new drug (IND) amendment to the Food and Drug Administration to commence a phase 2 study of its treatment for advanced ovarian cancer. The company also said it dosed the first patient in the phase 1 study of mRNA-2752, an intratumoral injection to treating metastatic solid tumor malignancies or lymphoma. Separately, the company said it and Merck & Co. Inc. are planning a phase 2 study comparing Moderna's personalized cancer vaccine (PCV) and Merck's Keytruda, against Keytruda alone. Monderna's stock has tumbled 12.5% over the past month through Monday, while Merck shares have slipped 1.7% and the Dow Jones Industrial Average has lost 3.5%.
Moderna, Inc. (MRNA), a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced recent updates to several of its immuno-oncology and rare disease programs and outlined its 2019-2020 corporate objectives. Moderna has 21 mRNA development candidates in its pipeline, with 11 programs now in clinical development.
Deals are rolling out during the first day of the J.P. Morgan Healthcare Conference and so, too, are the hotel meeting costs.
Moderna Therapeutics CEO Stéphane Bancel joins "Squawk Box" from the J.P. Morgan Health Care Conference to discuss what is coming down the pipeline in 2019.